Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome

Structure

Volumn 14, Issue 3, 2006, Pages 451-456

  Groll, Michael ^a   Berkers, Celia R ^b   Ploegh, Hidde L ^c,d   Ovaa, Huib ^b,c  

^a UNIVERSITY OF MUNICH   (Germany)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c HARVARD MEDICAL SCHOOL   (United States)

^d WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORONIC ACID DERIVATIVE; BORTEZOMIB; LEUCINE; PHENYLALANINE; PROTEASOME INHIBITOR;

ARTICLE; CATALYSIS; COMPLEX FORMATION; CRYSTAL STRUCTURE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SPECIFICITY; NONHUMAN; PRIORITY JOURNAL; YEAST;

ANIMALS; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CATALYTIC DOMAIN; CRYSTALLIZATION; LEUCINE; MAMMALS; MODELS, MOLECULAR; PEPTIDES; PHENYLALANINE; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN STRUCTURE, QUATERNARY; PYRAZINAMIDE; PYRAZINES; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY; YEASTS;

EID: 33644845743     PISSN: 09692126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.str.2005.11.019     Document Type: Article

References (43)

1. J. Adams, M. Behnke, S. Chen, A.A. Cruickshank, L.R. Dick, L. Grenier, J.M. Klunder, Y.T. Ma, L. Plamondon, and R.L. Stein Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids Bioorg. Med. Chem. Lett. 8 1998 333 338
2. C.R. Berkers, M. Verdoes, E. Lichtman, E. Fiebiger, B.M. Kessler, K.C. Anderson, H.L. Ploegh, H. Ovaa, and P.J. Galardy Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib Nat. Methods 2 2005 357 362
3. J.A. Brannigan, G. Dodson, H.J. Duggleby, P.C. Moody, J.L. Smith, D.R. Tomchick, and A.G. Murzin A protein catalytic framework with an N-terminal nucleophile is capable of self-activation Nature 378 1995 416 419
4. H.A. Braun, S. Umbreen, M. Groll, U. Kuckelkorn, I. Mlynarczuk, M.E. Wigand, I. Drung, P.M. Kloetzel, and B. Schmidt Tripeptide mimetics inhibit the 20 S proteasome by covalent bonding to the active threonines J. Biol. Chem. 280 2005 28394 28401
5. A.T. Brünger Assessment of phase accuracy by cross validation: the free R value. Methods and applications Acta Crystallogr. D Biol. Crystallogr. 49 1993 24 36
6. A. Brünger, P. Adams, G. Clore, W. DeLano, P. Gros, R. Grosse-Kunstleve, J. Jiang, J. Kuszewski, M. Nilges, and N. Pannu Crystallography & NMR system: a new software suite for macromolecular structure determination Acta Crystallogr. D Biol. Crystallogr. 1 1998 905 921
7. P. Chen, and M. Hochstrasser Autocatalytic subunit processing couples active site formation in the 20S proteasome to completion of assembly Cell 86 1996 961 972
8. P.J. Elliott, T.A. Soucy, C.S. Pien, J. Adams, and E.S. Lightcap Assays for proteasome inhibition Methods Mol. Med. 85 2003 163 172
9. M. Elofsson, U. Splittgerber, J. Myung, R. Mohan, and C.M. Crews Towards subunit-specific proteasome inhibitors: synthesis and evaluation of peptide alpha′,beta′-epoxyketones Chem. Biol. 6 1999 811 822
10. R. Engh, and R. Huber Accurate bond and angles parameters for X-ray protein structure refinement Acta Crystallogr. A 47 1991 392 400
11. G. Fenteany, R.F. Standaert, W.S. Lane, S. Choi, E.J. Corey, and S.L. Schreiber Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin Science 268 1995 726 731
12. M. Groll, and R. Huber Inhibitors of the eukaryotic 20S proteasome core particle: a structural approach Biochim. Biophys. Acta 1695 2004 33 44
13. M. Groll, and R. Huber Purification, crystallization and X-ray analysis of the yeast 20S proteasomes Methods Enzymol. 398 2005 329 336
14. M. Groll, L. Ditzel, J. Lowe, D. Stock, M. Bochtler, H.D. Bartunik, and R. Huber Structure of 20S proteasome from yeast at 2.4 Å resolution Nature 386 1997 463 471
15. M. Groll, W. Heinemeyer, S. Jager, T. Ullrich, M. Bochtler, D.H. Wolf, and R. Huber The catalytic sites of 20S proteasomes and their role in subunit maturation: a mutational and crystallographic study Proc. Natl. Acad. Sci. USA 96 1999 10976 10983
16. M. Groll, K.B. Kim, N. Kairies, R. Huber, and C.M. Crews Crystal structure of epoxomicin: 20S proteasome reveals a molecular basis for selectivity of alpha′,beta′-epoxyketone proteasome inhibitors J. Am. Chem. Soc. 122 2000 1237 1238
17. M. Groll, T. Nazif, R. Huber, and M. Bogyo Probing structural determinants distal to the site of hydrolysis that control substrate specificity of the 20S proteasome Chem. Biol. 9 2002 655 662
18. M. Groll, M. Bochtler, H. Brandstetter, T. Clausen, and R. Huber Molecular machines for protein degradation ChemBioChem 6 2005 222 256
19. J.L. Harris, P.B. Alper, J. Li, M. Rechsteiner, and B.J. Backes Substrate specificity of the human proteasome Chem. Biol. 8 2001 1131 1141
20. W. Heinemeyer, M. Fischer, T. Krimmer, U. Stachon, and D.H. Wolf The active sites of the eukaryotic 20 S proteasome and their involvement in subunit precursor processing J. Biol. Chem. 272 1997 25200 25209
21. A. Hershko, and A. Ciechanover The ubiquitin system Annu. Rev. Biochem. 67 1998 425 479
22. S. Jager, M. Groll, R. Huber, D.H. Wolf, and W. Heinemeyer Proteasome beta-type subunits: unequal roles of propeptides in core particle maturation and a hierarchy of active site function J. Mol. Biol. 291 1999 997 1013
23. A.F. Kisselev, and A.L. Goldberg Proteasome inhibitors: from research tools to drug candidates Chem. Biol. 8 2001 739 758
24. A.F. Kisselev, M. Garcia-Calvo, H.S. Overkleeft, E. Peterson, M.W. Pennington, H.L. Ploegh, N.A. Thornberry, and A.L. Goldberg The caspase-like sites of proteasomes, their substrate specificity, new inhibitors and substrates, and allosteric interactions with the trypsin-like sites J. Biol. Chem. 278 2003 35869 35877
25. E.S. Lightcap, T.A. McCormack, C.S. Pien, V. Chau, J. Adams, and P.J. Elliott Proteasome inhibition measurements: clinical application Clin. Chem. 46 2000 673 683
26. R.E. London, and S.A. Gabel Development and evaluation of a boronate inhibitor of gamma-glutamyl transpeptidase Arch. Biochem. Biophys. 385 2001 250 258
27. R.E. London, and S.A. Gabel Formation of a trypsin-borate-4-aminobutanol ternary complex Biochemistry 41 2002 5963 5967
28. J. Löwe, D. Stock, B. Jap, P. Zwickl, W. Baumeister, and R. Huber Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 Å resolution Science 268 1995 533 539
29. H. Ludwig, D. Khayat, G. Giaccone, and T. Facon Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies Cancer. 104 2005 1794 1807
30. V.R. Macherla, S.S. Mitchell, R.R. Manam, K.A. Reed, T.H. Chao, B. Nicholson, G. Deyanat-Yazdi, B. Mai, P.R. Jensen, and W.F. Fenical Structure-activity relationship studies of salinosporamide A (NPI-0052), a novel marine derived proteasome inhibitor J. Med. Chem. 48 2005 3684 3687
31. T. Nazif, and M. Bogyo Global analysis of proteasomal substrate specificity using positional-scanning libraries of covalent inhibitors Proc. Natl. Acad. Sci. USA 98 2001 2967 2972
32. A.K. Nussbaum, T.P. Dick, W. Keilholz, M. Schirle, S. Stevanovic, K. Dietz, W. Heinemeyer, M. Groll, D.H. Wolf, and R. Huber Cleavage motifs of the yeast 20S proteasome beta subunits deduced from digests of enolase 1 Proc. Natl. Acad. Sci. USA 95 1998 12504 12509
33. M. Orlowski, C. Cardozo, and C. Michaud Evidence for the presence of five distinct proteolytic components in the pituitary multicatalytic proteinase complex: properties of two components cleaving bonds on the carboxyl side of branched chain and small neutral amino acids Biochemistry 32 1993 1563 1572
34. Z. Otwinowski, and W. Minor Processing of X-ray diffraction data collected in oscillation mode Methods Enzymol. 276 1997 307 326
35. Z. Otwinowski, D. Borek, W. Majewski, and W. Minor Multiparametric scaling of diffraction intensities Acta Crystallogr. A 59 2003 228 234
36. P.G. Richardson, P. Sonneveld, M.W. Schuster, D. Irwin, E.A. Stadtmauer, T. Facon, J.L. Harousseau, D. Ben-Yehuda, S. Lonial, and H. Goldschmidt Bortezomib or high-dose dexamethasone for relapsed multiple myeloma N. Engl. J. Med. 352 2005 2487 2498
37. B.A. Teicher, G. Ara, R. Herbst, V.J. Palombella, and J. Adams The proteasome inhibitor PS-341 in cancer therapy Clin. Cancer Res. 5 1999 2638 2645
38. T.R. Transue, J.M. Krahn, S.A. Gabel, E.F. DeRose, and R.E. London X-ray and NMR characterization of covalent complexes of trypsin, borate, and alcohols Biochemistry 43 2004 2829 2839
39. Turk, D. (1992). Improvement of a programm for molecular graphics and manipulation of electron densities and its application for protein structure determination. Thesis, Technische Universitaet Muenchen, Germany.
40. M. Unno, T. Mizushima, Y. Morimoto, Y. Tomisugi, K. Tanaka, N. Yasuoka, and T. Tsukihara The structure of the mammalian 20s proteasome at 2.75 Å resolution Structure 10 2002 609 618
41. A. Vinitsky, C. Michaud, J.C. Powers, and M. Orlowski Inhibition of the chymotrypsin-like activity of the pituitary multicatalytic proteinase complex Biochemistry 31 1992 9421 9428
42. B. Walker, and J.F. Lynas Strategies for the inhibition of serine proteases Cell. Mol. Life Sci. 58 2001 596 624
43. P.C. Weber, S.L. Lee, F.A. Lewandowski, M.C. Schadt, C.W. Chang, and C.A. Kettner Kinetic and crystallographic studies of thrombin with Ac-(D)Phe-Pro-boroArg-OH and its lysine, amidine, homolysine, and ornithine analogs Biochemistry 34 1995 3750 3757